2024-03-10 00:54:52 ET
Summary
- Alnylam has pushed back the data readout for its HELIOS-B trial from early 2024 to June/July 2024, causing a 10% decline in the stock price.
- The company has made changes to the study duration, primary endpoint, and secondary endpoints of the trial, raising concerns among investors.
- The changes suggest that Alnylam may be facing challenges in achieving statistically significant results and demonstrating the superiority of its drug, vutrisiran, over the current front-line treatment for ATTR-CM, tafamidis.
Alnylam ( ALNY ) surprised investors with the announcement of pushing back the HELIOS-B data readout from early 2024 to June/July 2024. Analysts and investors were left trying to read the tea leaves of what this delay means for the odds of clinical success. It’s unusual for a Phase 3 trial endpoint to be abruptly changed at a time when investors were imminently expecting the data readout based on what the company stated just a few months prior. The uncertainty created a sizeable drop in the stock price. The question that needs to be answered is whether this change is a red flag or simply a smart move by management. This article will detail the changes being made in the trial and whether it warrants cause for concern....
Read the full article on Seeking Alpha
For further details see:
Is Alnylam's HELIOS-B Delay A Red Flag?